Nisa Leung

Add links
From Wikipedia, the free encyclopedia

Nisa Leung (Chinese:梁颕宇 or 梁颖宇) is a venture capitalist and managing partner at Qiming Venture Partners. She has been named on the Forbes Midas List for five consecutive years in 2019, 2020, 2021,2022 and 2023.[1][2][3][4][5] and Best Women Venture Capitalists by Forbes China for three years.[6][7][8] Nisa was also named one of the Most Powerful Women in Business in China by Fortune China in 2022 and 2023.[9] Nisa is widely known as China's leading investor in healthcare.[10][11][12][13]

Education[edit]

Nisa earned a Bachelor of Science degree from Cornell University and graduated from Stanford Graduate School of Business in 2001 with an MBA.

Career[edit]

Nisa started her career in healthcare investment after realizing there was a lack of advanced therapeutics in China when her family was seeking treatments for her distant uncle, who was diagnosed with liver cancer.[14][15]

Prior to joining Qiming Venture Partners in 2006, she co-founded Biomedic Holdings, which had operations and investments in medical devices, pharmaceuticals, and health care services in China including Novamed Pharmaceuticals (acquired by SciClone NASDAQ:SCLN) and U-Systems (acquired by GE Healthcare). She was also Venture Partner of PacRim Ventures in Menlo Park and was previously with Softbank/Mobius Venture Capital.[16]

Leading Qiming's healthcare investments, Nisa has backed nearly 200 healthcare companies.[17] She currently sits on the board of Zai Lab (NASDAQ:ZLAB; HKSE:9688), CanSino Biologics(SSE:688185; HKSE:6185), Caidya, Chain Medical Labs, Belief BioMed, Zencore Biologics, Valgen MedTech, Alamar Biosciences among others. Her other investments include Gan&Lee (SSE:603087), New Horizon Health (HKSE:6606), Berry Genomics (SZSE:000710), CITIC Pharma (acquired by Shanghai Pharmaceutical HKSE: 2607), Crown Bioscience (acquired by JSR Life Sciences), Aeonmed Medical, Novast Pharmaceuticals, Nurotron, Origene Technologies (acquired by VCAN Bio SSE:600645), Richen, Vision Pro, MEDx, Cure Genetics, Goodwill (SSE:688246), SinoCellTech (SSE:688520), Sino Biological (SZSE:301047), Apollomics (NASDAQ:APLM), SinoUnited Health, Schrödinger (NASDAQ:SDGR), Recursion (NASDAQ:RXRX), Insilico Medicine, Structure Therapeutics (NASDAQ:GPCR), Jacobio (HKSE:1167), Hope Medicine, Sinotau, PlusLife among others.[18]

Nisa is recognized as playing a key role in China's biotech boom and innovation.[19][20]

She serves as Independent Non-executive Director of the Hong Kong Exchanges and Clearing Limited.[21] She is also a visiting lecturer at Harvard Law School,[22] member of Stanford Graduate School of Business Advisory Council,[23] Council Member of China Pharmaceutical Innovation and Research Development Association (PhIRDA), Founding Member and Chair of Pharmaceutical Innovation Investment Specialty Committee of PhIRDA. [24]

References[edit]

  1. ^ "No. 54 Nisa Leung". Forbes. Retrieved 2023-04-19.
  2. ^ Flannery, Russell. "Mom's Encouragement Lands China Healthcare Investor On 2020 Forbes Midas List". Forbes. Retrieved 2023-04-19.
  3. ^ Standard, The. "Qiming's Duane Kuang, Nisa Leung named on 2021 Forbes Midas List". The Standard. Retrieved 2023-04-19.
  4. ^ "Nisa Leung". Forbes. Retrieved 2023-04-19.
  5. ^ "The Midas List 2023". Forbes. Retrieved 2023-05-06.
  6. ^ Forbes China (2023-01-16). "福布斯中国2023女性创投人20揭晓：用敏锐、坚韧应对不确定性". Forbes China 福布斯中国.
  7. ^ Forbes China (2022-03-24). "福布斯中国发布2022年中国女性创投人20". Forbes China 福布斯中国.
  8. ^ Forbes China (2023-04-19). "2018福布斯中国最佳女性创投人TOP25". Forbes China 福布斯中国.
  9. ^ "梁颕宇". 财富中文网 (in Chinese (China)). Retrieved 2023-04-19.
  10. ^ Wang, Catherine. "How China's Leading Female Healthcare Investor Backs Billion-Dollar Biotech Companies". Forbes. Retrieved 2023-04-19.
  11. ^ Ngui, Yantoultra; Daga, Anshuman; Ngui, Yantoultra (2022-09-27). "'Overinvested' China healthcare sector set for shake up, top venture fund says". Reuters. Retrieved 2023-04-19.
  12. ^ "NISA LEUNG : Pioneering HK investor driven by improving lives and world-changing technologies". www.hkstpnewsroom.com. Retrieved 2023-04-19.
  13. ^ Forbes China (2021-04-15). "连续三年唯一上榜的中国医疗健康投资人，启明创投梁颕宇怎么看投资机会 | 全球最佳创投人榜". Forbes China 福布斯中国.
  14. ^ "Investing in China: It's Still "the Wild, Wild West"". Stanford Graduate School of Business. 31 January 2023. Retrieved 2023-04-19.
  15. ^ Wang, Catherine. "How China's Leading Female Healthcare Investor Backs Billion-Dollar Biotech Companies". Forbes. Retrieved 2023-04-19.
  16. ^ "Nisa Leung | Qiming Venture Partners". www.qimingvc.com. Retrieved 2023-04-19.
  17. ^ "【2023投资风向标】对话启明创投：医疗创新由点向面推进，重点关注跨界融合与效率提升_腾讯新闻". new.qq.com. Retrieved 2023-04-19.
  18. ^ "Nisa Leung | Qiming Venture Partners". www.qimingvc.com. Retrieved 2023-04-19.
  19. ^ Capital, TrueBridge. "The Midas List 2022: Return Of The Top Female Investors". Forbes. Retrieved 2023-04-19.
  20. ^ "创业迷梁颕宇，批量收割医疗投资 | 界面 · 财经号". m.jiemian.com. Retrieved 2023-04-19.
  21. ^ "LEUNG Nisa Bernice Wing-Yu". www.hkexgroup.com. Retrieved 2023-04-19.
  22. ^ "HarvardKey - Harvard University Authentication Service". www.pin1.harvard.edu. Retrieved 2023-04-19.
  23. ^ "Advisory Council Members". Stanford Graduate School of Business. Retrieved 2023-04-19.
  24. ^ "专委会". www.phirda.com. Retrieved 2023-04-19.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Nisa_Leung&oldid=1203545502"